0001399529-21-000084.txt : 20210505 0001399529-21-000084.hdr.sgml : 20210505 20210505161937 ACCESSION NUMBER: 0001399529-21-000084 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210503 FILED AS OF DATE: 20210505 DATE AS OF CHANGE: 20210505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Paglia Regina M. CENTRAL INDEX KEY: 0001813985 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36281 FILM NUMBER: 21893617 MAIL ADDRESS: STREET 1: C/O DICERNA PHARMACEUTICALS, INC. STREET 2: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc CENTRAL INDEX KEY: 0001399529 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205993609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617 621 8097 MAIL ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 wf-form4_162024595832896.xml FORM 4 X0306 4 2021-05-03 0 0001399529 Dicerna Pharmaceuticals Inc DRNA 0001813985 Paglia Regina M. C/O DICERNA PHARMACEUTICALS, INC. 75 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Human Resources Officer Common Stock 2021-05-03 4 M 0 4431 12.93 A 4431 D Common Stock 2021-05-03 4 S 0 3956 30.1692 D 475 D Common Stock 2021-05-03 4 S 0 475 31.2485 D 0 D Employee Stock Option (Right to Buy) 12.93 2021-05-03 4 M 0 4431 0 D 2029-02-28 Common Stock 4431.0 127845 D The Reporting Person sold an aggregate of 4,431 shares of Common Stock on May 3, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 1.54% of 287,026 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2020. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.73 to $30.665, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.75 to $31.66, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. The option vested 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date. /s/ Douglas W. Pagan, attorney-in-fact 2021-05-05